BioVaxys Technology Corp.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BIOV.CN research report →
Companywww.biovaxys.com
BioVaxys Technology Corp. , a clinical biotechnology company, develops antiviral and anticancer vaccine platforms. It develops BVX-0320, a monovalent SARS-CoV-2 vaccine; and BVX-0918A, a haptenized tumor cell vaccine for ovarian cancer, as well as CoviDTH, which screens for an immune system response in patients exposed to SARS-CoV-2.
- CEO
- James Christopher Passin
- IPO
- 2018
- Employees
- 3
- HQ
- Etobicoke, BC, CA
Price Chart
Valuation
- Market Cap
- $2.04M
- P/E
- -0.62
- P/S
- 0.00
- P/B
- -0.56
- EV/EBITDA
- -0.87
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 121.88%
- ROIC
- 95.65%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-3,954,781 · 48.55%
- EPS
- $-0.20 · 64.75%
- Op Income
- $-3,295,516
- FCF YoY
- -176.68%
Performance & Tape
- 52W High
- $0.40
- 52W Low
- $0.03
- 50D MA
- $0.08
- 200D MA
- $0.20
- Beta
- 1.01
- Avg Volume
- 181.88K
Get TickerSpark's AI analysis on BIOV.CN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our BIOV.CN Coverage
We haven't published any research on BIOV.CN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate BIOV.CN Report →